NX-1207

Generic Name
NX-1207
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
9L8TV1O7E0
Background

NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

Indication

Investigated for use/treatment in benign prostatic hyperplasia.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Phase 3
Terminated
Conditions
Lower Urinary Tract Symptoms
Interventions
Drug: NX-1207
Drug: Tamsulosin
First Posted Date
2013-12-06
Last Posted Date
2022-05-26
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
104
Registration Number
NCT02003742
Locations
🇩🇪

Klinikum der Ludwig-Maximilians-universität München, Munich, Germany

🇮🇹

Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy

🇵🇱

Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland

and more 2 locations

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

First Posted Date
2013-05-03
Last Posted Date
2017-03-10
Lead Sponsor
Nymox Corporation
Target Recruit Count
160
Registration Number
NCT01846793
Locations
🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669., Dallas, Texas, United States

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Phase 3
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
Drug: NX-1207
First Posted Date
2011-09-22
Last Posted Date
2014-04-30
Lead Sponsor
Nymox Corporation
Target Recruit Count
192
Registration Number
NCT01438775
Locations
🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669., Houston, Texas, United States

🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669, San Antonio, Texas, United States

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

First Posted Date
2009-07-24
Last Posted Date
2017-03-10
Lead Sponsor
Nymox Corporation
Target Recruit Count
500
Registration Number
NCT00945490
Locations
🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669., Richmond, Virginia, United States

🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669, Grand Rapids, Michigan, United States

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Phase 3
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
Drug: NX-1207
Drug: Placebo
First Posted Date
2009-06-11
Last Posted Date
2014-04-30
Lead Sponsor
Nymox Corporation
Target Recruit Count
500
Registration Number
NCT00918983
Locations
🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669, Bala Cynwyd, Pennsylvania, United States

🇺🇸

For information concerning this clinical site, please contact Nymox at 800-936-9669., Salt Lake City, Utah, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy